Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 – PRnews Leader
Posted: November 4, 2020 at 11:59 am
The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism
Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.
There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.
To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link
Key Market Insights
Over 280 stem cell therapies are under development, most of which are allogeneic productsMore than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.
70% of pipeline candidates are based on mesenchymal stem cellsIt is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.
Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regionsWithin these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies
Over 1,500 grants were awarded for stem cell research, since 2015More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.
Outsourcing has become indispensable to R&D and manufacturing activity in this domainPresently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.
North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.
To request a sample copy / brochure of this report, please visit this link
Key Questions Answered
The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:
The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.
For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html
or email [emailprotected]
You may also be interested in the following titles:
Contact:
Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]
Read the rest here:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader
- CAR T cell therapy explained: Cancer types, success rate, and more - Medical News Today - March 24th, 2021
- UK deal sees consolidation of two players in the iPSC space - BioPharma-Reporter.com - March 24th, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally... - March 24th, 2021
- Stem Cell Therapy Market Evaluation of Industry Trends, Growth Drivers and Forecast To 2025 NeighborWebSJ - NeighborWebSJ - February 25th, 2021
- Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in... - February 25th, 2021
- Scientists have Created a 'Brain in a Dish.' It Could Potentially Cure Alzheimer, Dementia - News18 - February 25th, 2021
- Exosome therapeutic Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 KSU | The Sentinel Newspaper - KSU | The... - February 25th, 2021
- 2021 Updates in Autologous Stem Cell Based Therapies Industry with Global Market Demand Analysis, Industry Chain, Revenue and Forecast 2026 - The... - February 25th, 2021
- [Full text] A Comprehensive Review on Factors Influences Biogenesis, Functions, Th | IJN - Dove Medical Press - February 17th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 17th, 2021
- bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) - BioSpace - February 17th, 2021
- Beti-Cel Gene Therapy Frees Patients With Beta-Thalassemia From Red Blood Cell Transfusions - OncLive - February 17th, 2021
- Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire - February 9th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - Yahoo Finance UK - February 4th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 4th, 2021
- Stem Cell Study Illuminates the Cause of a Devastating Inherited Heart Disorder - Newswise - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Worldwide Industry for Biopreservation to 2026 - Key Drivers, Restraints and Opportunities - Yahoo Finance - January 5th, 2021
- Vape Flavorings Are Cardiotoxic and Can Damage the Heart - SciTechDaily - December 28th, 2020
- Outlook on the Biopreservation Global Market to 2026 - Profiling Avantor, BioLife Solutions and ThermoGenesis Among Others - GlobeNewswire - December 26th, 2020
- UC Davis researchers find a way to help stem cells work ... - December 17th, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 17th, 2020
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 17th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 17th, 2020
- Network of Genes Involved in Congenital Heart Disease Identified - Technology Networks - December 17th, 2020
- Industry News: Hamamatsu Photonics UK Ltd and the Medical Technologies Innovation Facility enter into a partnership agreement - SelectScience - December 17th, 2020
- Osteoporosis treatments could be on the way after scientists identify aging gene - iNews - November 30th, 2020
- Global Myocardial Infarction Drug Market to have sustainable growth over the forecast period 2020-2028| Leading Players BioCardia, Inc., Laboratoires... - November 30th, 2020
- Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice - November 24th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 24th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 24th, 2020
- 3D Cardiac Mapping Systems Market Competitive Landscape Analysis with Forecast by 2028 - The Haitian-Caribbean News Network - November 24th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 18th, 2020
- Mimicking the early development of the heart - Tech Explorist - November 18th, 2020
- Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.com - Business Wire - November 18th, 2020
- UPDATED: Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? - Endpoints News - November 18th, 2020
- Can Hearts Repair Themselves Via Stem Cells - The Niche - November 13th, 2020
- Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs ... - November 13th, 2020
- Global Autologous Stem Cell Based Therapies Market 2020 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2025 - The... - November 13th, 2020
- The Amniotic Fluid Stem Cell Therapy market to be in conjunction to growth from 2018 to 2026 - PRnews Leader - November 13th, 2020
- BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights - GlobeNewswire - November 13th, 2020
- Exploring Genetic Variation and COVID-19 Clinical Variability - Technology Networks - November 13th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 10th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 10th, 2020
- Global Progenitor Cell Product Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2026 - Zenit News - November 10th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients... - November 10th, 2020
- Advancement: Know the Rapid Growth Factors of Biopreservation Market| Stay Up-To-Date With Emerging - PharmiWeb.com - November 10th, 2020
- California Prop 14 would keep taxpayer funding of stem cell therapy research, which can change lives: Meet the Langenhop kids - AZCentral.com - November 4th, 2020
- Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition - Business Wire - November 4th, 2020
- Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over2017 2025 - Royal Sutton News - November 4th, 2020
- Autologous Stem Cell Based Therapies Market to Witness Increase in Revenues by 2020-2026 - PRnews Leader - November 3rd, 2020
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire - November 3rd, 2020
- Ready To Use Autologous Stem Cell Based Therapies Market Industry Analysis, Trend and Growth, 2020-2020 - Royal Sutton News - November 1st, 2020
- Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire - November 1st, 2020
- Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser - November 1st, 2020
- The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients - DocWire News - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Stem Cell Assay Market expected to Witness a Sustainable Growth over 2025 - TechnoWeekly - October 23rd, 2020
- Exosome Therapeutic Market 2020-2026 Demand Analysis and Projected Huge Growth by Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 23rd, 2020
- Stem Cell Assay Market In-Depth Analysis & Forecast 2017-2025 - The Think Curiouser - October 22nd, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 22nd, 2020
- Exosome Therapeutic Market 2020-2026 to Witness Excellent Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 22nd, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 16th, 2020
- Global Cell Based Assay & High Content Screening Markets to 2024: Updated Report - Understand Growth Expectations and the Potential Market Size -... - October 16th, 2020
- Merck Presents Three-Year Survival Data for KEYTRUDA (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational... - October 16th, 2020
- Preclinical Study Shows Improvement In Recovery From Heart Attack With Exosomes - Anti Aging News - October 10th, 2020
- Autologous Stem Cell Based Therapies Market Size, Business Revenue Forecast, Leading Competitors And Growth Trends 2026| Regeneus, Mesoblast,... - October 10th, 2020
- Recording thousands of nerve cell impulses at high resolution - Newswise - October 4th, 2020
- Wisconsin Medicine Livestream: The future of medicine - Wisbusiness.com - October 2nd, 2020
- Measuring chips amplify and record nerve cells - Futurity: Research News - October 2nd, 2020
- Recording thousands of nerve cell impulses at high resolution - ScienceDaily - Up News Info - October 2nd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 30th, 2020
- Heart attack patches may save lives in US and beyond - Galveston County Daily News - September 30th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2025 Global Briefing, Growth Analysis And Opportunities Outlook | Major Giants ... - September 30th, 2020
- Exosome Therapeutic Market Latest Industry Size, Growth, Share, Emerging Demands, and Competitive Landscape || Major Gaints Jazz Pharmaceuticals,... - September 30th, 2020
- James T. Willerson, Revered Clinician, Editor, and Mentor, Dies at 81 - TCTMD - September 22nd, 2020
- Researchers Discover a Way To Create Induced Tropoblast Stem Cells - Technology Networks - September 18th, 2020
- What Is Covid-19 Doing to Our Hearts? - The New Republic - September 18th, 2020
- Astellas and Seattle Genetics Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated... - September 18th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - BioSpace - September 14th, 2020